Key Highlights
- Akebia Therapeutics shares are down 23% in pre-market trading despite a headline earnings beat.
- The VOICE trial was stopped early after an interim analysis showed significant superiority for the treatment arm.
- Q2 2026 net product revenue rose 34% sequentially to $21.3 million.
- Total revenues came in at $49.1 million, down from $62.5 million in Q2 2025 on lower Auryxia sales.
- The company lowered its full-year 2027 unit volume guidance due to planned pricing changes.
Stock Falls Despite Headline Beat
Akebia Therapeutics shares are trading sharply lower today, even though the company technically reported second-quarter results that beat consensus estimates on both revenue and earnings per share. The stock fell as much as 23.00% to $0.99 in pre-market trading, extending a 2.27% decline from the prior regular session. The disconnect between the reported beat and the stock's sharp drop suggests investors are focused on other details in the report.
Net product revenue for Vafseo grew 34% sequentially to $21.3 million, surpassing 10,500 patients on therapy, up approximately 47% quarter over quarter. However, total revenues of $49.1 million were down from $62.5 million in the same period a year earlier due to lower Auryxia sales, and net loss widened to $8.9 million versus net income of $0.2 million a year ago.
Trial Halted Early, Guidance Lowered
A key factor likely weighing on the stock is news that the VOICE trial, run by U.S. Renal Care, was stopped early after an interim analysis showed statistically significant superiority in the composite endpoint of all-cause mortality and hospitalization, with a hazard ratio of 0.16 and a 10% reduction in hospitalization. While the trial results themselves were positive, early stoppage of a trial can raise questions among investors about statistical robustness and next steps.
Management also lowered its 2027 unit volume guidance, citing planned repricing within the range of ESAs set to occur before the TDAPA period ends on December 31, 2026. This guidance cut, layered on top of the mixed revenue picture, appears to be weighing more heavily on shares than the underlying earnings beat.
About Akebia Therapeutics
Akebia Therapeutics is a fully integrated biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing and commercializing novel therapeutics for patients living with kidney disease. The company's commercial portfolio includes Auryxia, an FDA approved treatment for controlling serum phosphorus levels in adults with chronic kidney disease, and Vafseo, an oral hypoxia inducible factor prolyl hydroxylase inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease.
Pipeline and Commercial Progress
Beyond Vafseo, Akebia continues to advance its pipeline, including a Phase 2 trial of AKB-9090 and Phase 1 studies of AKB-10108 targeting critical care indications. Commercial momentum for Vafseo continued with about a third of U.S. Renal Care prescribers now onboard, alongside increased clinical engagement at DaVita and a commercial reorganization aimed at improving field trade efficiency ahead of broader adoption expected into 2027.
Conclusion
Despite reporting revenue and earnings that beat consensus estimates, Akebia Therapeutics shares are down sharply as investors weigh the early stoppage of the VOICE trial and lowered 2027 volume guidance more heavily than the headline results. The coming weeks will likely bring further clarity on the durability of Vafseo's commercial ramp.
Why is Akebia Therapeutics stock down today despite an earnings beat?
Shares are falling as investors focus on the early stoppage of the VOICE trial and the company's lowered 2027 unit volume guidance rather than the headline earnings beat.
What is Vafseo?
Vafseo is Akebia's oral hypoxia inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease.
Why was the VOICE trial stopped early?
The trial was stopped after an interim analysis showed statistically significant superiority in the composite endpoint of all-cause mortality and hospitalization.
This article is for informational purposes only and does not constitute financial, investment, or trading advice. Readers should conduct their own research or consult a licensed financial advisor before making any investment decisions.






Please wait processing your request...